Twist Bioscience (NASDAQ:TWST) Reaches New 12-Month High – What’s Next?

Shares of Twist Bioscience Corporation (NASDAQ:TWST) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $80.79 and last traded at $78.9580, with a volume of 233794 shares traded. The stock had previously closed at $76.17.

Wall Street Analysts Forecast Growth

TWST has been the subject of several research analyst reports. Guggenheim raised their price target on Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. UBS Group set a $89.00 price target on Twist Bioscience in a research report on Monday. Piper Sandler initiated coverage on Twist Bioscience in a research report on Thursday. They set an “overweight” rating and a $85.00 price target for the company. Leerink Partners set a $80.00 target price on Twist Bioscience in a report on Friday, May 22nd. Finally, TD Cowen set a $89.00 target price on Twist Bioscience in a research report on Monday. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $71.60.

Twist Bioscience Price Performance

The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70. The company has a 50-day simple moving average of $59.67 and a 200-day simple moving average of $47.58. The company has a market cap of $5.10 billion, a price-to-earnings ratio of -61.57 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The firm had revenue of $110.72 million during the quarter, compared to analyst estimates of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business’s revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.66) EPS. As a group, research analysts predict that Twist Bioscience Corporation will post -2.02 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Jan Johannessen sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $56.12, for a total value of $673,440.00. Following the sale, the director owned 17,754 shares in the company, valued at $996,354.48. This represents a 40.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 8,061 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $65.29, for a total value of $526,302.69. Following the completion of the sale, the chief executive officer owned 858,887 shares in the company, valued at approximately $56,076,732.23. This represents a 0.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 43,170 shares of company stock worth $2,418,964. 3.08% of the stock is owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. ARK Investment Management LLC lifted its stake in Twist Bioscience by 12.4% in the 4th quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after buying an additional 832,687 shares in the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of Twist Bioscience by 26.7% during the 3rd quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock worth $180,403,000 after purchasing an additional 1,349,867 shares during the period. William Blair Investment Management LLC lifted its stake in shares of Twist Bioscience by 43.7% during the 4th quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after purchasing an additional 1,812,146 shares during the period. EdgePoint Investment Group Inc. lifted its stake in shares of Twist Bioscience by 31.7% during the 4th quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock worth $170,590,000 after purchasing an additional 1,295,672 shares during the period. Finally, State Street Corp lifted its stake in shares of Twist Bioscience by 17.4% during the 4th quarter. State Street Corp now owns 3,627,818 shares of the company’s stock worth $115,074,000 after purchasing an additional 538,755 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.